{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:03:37Z","timestamp":1794395017738,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11892-5","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:35:46Z","timestamp":1761903346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Wen-qiang","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-feng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"11892_CR1","unstructured":"Acute bacterial skin. and skin structure infections: developing drugs for treatment. https:\/\/www.fda.gov\/media\/71052\/download."},{"issue":"6","key":"11892_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1469-0691.2012.03914.x","volume":"19","author":"BY Lee","year":"2013","unstructured":"Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19(6):528\u201336.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"11892_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa055356","volume":"355","author":"GJ Moran","year":"2006","unstructured":"Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666\u201374.","journal-title":"N Engl J Med"},{"issue":"4","key":"11892_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","volume":"48","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr., Amin A, Ford WT Jr., Finley R, Kaye KS, Nguyen HH, Rybak MJ, Talan D. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508\u201319.","journal-title":"J Emerg Med"},{"key":"11892_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-6-2","volume":"6","author":"JA Delaney","year":"2008","unstructured":"Delaney JA, Schneider-Lindner V, Brassard P, Suissa S. Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community. BMC Med. 2008;6:2.","journal-title":"BMC Med"},{"issue":"Suppl 1","key":"11892_CR6","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0924-8579(09)70541-2","volume":"34","author":"MS Dryden","year":"2009","unstructured":"Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents. 2009;34(Suppl 1):S2-7.","journal-title":"Int J Antimicrob Agents"},{"key":"11892_CR7","unstructured":"China Antimicrobial Surveillance Network. http:\/\/www.chinets.com\/Document."},{"issue":"4","key":"11892_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijantimicag.2011.09.030","volume":"39","author":"S Stefani","year":"2012","unstructured":"Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents. 2012;39(4):273\u201382.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"11892_CR9","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"2","key":"11892_CR10","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2014;59(2):e10\u201352.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"1","key":"11892_CR11","doi-asserted-by":"publisher","first-page":"12689","DOI":"10.1038\/s41598-020-69058-zIF:3.9Q1B3","volume":"10","author":"A Shariati","year":"2020","unstructured":"Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep. 2020;10(1):12689.","journal-title":"Sci Rep"},{"issue":"4","key":"11892_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/phar.1577","volume":"35","author":"DM Gomes","year":"2015","unstructured":"Gomes DM, Ward KE, LaPlante KL. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus. Pharmacotherapy. 2015;35(4):424\u201332.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"11892_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s15010-020-01568-4","volume":"49","author":"H Ishaq","year":"2021","unstructured":"Ishaq H, Tariq W, Talha KM, Palraj BRV, Sohail MR, Baddour LM, et al. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis. Infection. 2021;49(5):803\u201311.","journal-title":"Infection"},{"issue":"6","key":"11892_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Lodise TP, Paterson DL. The clinical significance of Vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755\u201371.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"11892_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1086\/650574","volume":"50","author":"G Morales","year":"2010","unstructured":"Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sanchez-Garcia M. Resistance to linezolid is mediated by the Cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2010;50(6):821\u20135.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"5","key":"11892_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.coph.2010.06.006","volume":"10","author":"E Nannini","year":"2010","unstructured":"Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol. 2010;10(5):516\u201321.","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl 3","key":"11892_CR17","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1093\/cid\/ciz004","volume":"68","author":"Y Golan","year":"2019","unstructured":"Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2019;68(Suppl 3):S206\u201312.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"12","key":"11892_CR18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/phar.2185","volume":"38","author":"KE Barber","year":"2018","unstructured":"Barber KE, Bell AM, Wingler MJB, Wagner JL, Stover KR. Omadacycline enters the ring: a new antimicrobial contender. Pharmacotherapy. 2018;38(12):1194\u2013204.","journal-title":"Pharmacotherapy"},{"key":"11892_CR19","doi-asserted-by":"crossref","unstructured":"Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS. Antimicrobial activity of Omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and taiwan: results from the SENTRY antimicrobial surveillance program (2013 to 2016). Antimicrob Agents Chemother. 2019;63(3):e02262-18.","DOI":"10.1128\/AAC.02262-18"},{"key":"11892_CR20","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of Omadacycline activity tested against clinical isolates from the united States and europe: report from the SENTRY antimicrobial surveillance Program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488-19.","DOI":"10.1128\/AAC.02488-19"},{"issue":"4","key":"11892_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","volume":"59","author":"KA Rodvold","year":"2020","unstructured":"Rodvold KA, Burgos RM, Tan X, Pai MP. Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2020;59(4):409\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"11892_CR22","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","volume":"69","author":"S Opal","year":"2019","unstructured":"Opal S, File TM, van der Poll T, Tzanis E, Chitra S, McGovern PC. An integrated safety summary of Omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2019;69(Suppl 1):S40\u20137.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"9","key":"11892_CR23","first-page":"449","volume":"11","author":"K LaPensee","year":"2018","unstructured":"LaPensee K, Lodise T. Potential Cost-Savings with Once-Daily aminomethylcycline antibiotic versus Vancomycin in hospitalized patients with acute bacterial skin and skin structure infections. Am Health Drug Benefits. 2018;11(9):449\u201359.","journal-title":"Am Health Drug Benefits"},{"issue":"9","key":"11892_CR24","first-page":"488","volume":"11","author":"Na list","year":"2018","unstructured":"list Na. Improved quality of life in adults with acute bacterial skin and skin structure infections with omadacycline or linezolid therapy. Am Health Drug Benefits. 2018;11(9):488.","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"11892_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397.","journal-title":"Res Synth Methods"},{"issue":"11","key":"11892_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"2","key":"11892_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254\u201362.","journal-title":"Clin Infect Dis"},{"key":"11892_CR28","unstructured":"Addendum to the note for guidance on evaluation of medicinal products. indicated for treatment of bacterial infections (CHMP\/EWP\/558\/95 REV 2) to address indication-specific clinical data (draft). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections\/ewp\/558\/95-rev-2-address-indication-specific-clinical-data_en.pdf."},{"key":"11892_CR29","unstructured":"Cochrane. Handbook for Systematic Reviews of Interventions version 6.3. (updated February 2022). https:\/\/www.training.cochrane.org\/handbook."},{"key":"11892_CR30","unstructured":"Chapter 8. Assessing risk of bias in a randomized trial. https:\/\/www.training.cochrane.org\/handbook."},{"issue":"11","key":"11892_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"10","key":"11892_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8(10):e76654.","journal-title":"PLoS ONE"},{"issue":"7\u20138","key":"11892_CR33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344.","journal-title":"Stat Med"},{"issue":"2","key":"11892_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"11892_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3(2):161\u201376.","journal-title":"Res Synth Methods"},{"key":"11892_CR36","unstructured":"Efficacy. and Safety of Ceftaroline versus linezolid in subjects with complicated skin and skin structure infections. https:\/\/clinicaltrials.gov\/study\/NCT00633152?term=NCT00633152&rank=1 ."},{"key":"11892_CR37","unstructured":"Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection. https:\/\/clinicaltrials.gov\/study\/NCT03747497?term=NCT03747497&rank=1."},{"key":"11892_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0518-2","volume":"8","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wang Y, Van Driel ML, McGuire TM, Zhang T, Dong Y, et al. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control. 2019;8:72.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"11892_CR39","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1186\/s12879-021-06736-xIF:3.0Q2B3","volume":"21","author":"I Vlachaki","year":"2021","unstructured":"Vlachaki I, Vacchelli M, Zinzi D, Falla E, Jiang Y, Mantopoulos T, et al. Comparative efficacy of Delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis. BMC Infect Dis. 2021;21(1):1036.","journal-title":"BMC Infect Dis"},{"issue":"34","key":"11892_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030120","volume":"101","author":"H Li","year":"2022","unstructured":"Li H, Liang X, Mo G, Guo S, Chen X, Li Y. Efficacy and safety of optional parenteral antimicrobial therapy for complicated skin and soft tissue infections: a systematic review and bayesian network meta-analysis. Medicine. 2022;101(34):e30120.","journal-title":"Medicine"},{"issue":"8","key":"11892_CR41","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1185\/03007995.2015.1058248","volume":"31","author":"H Thom","year":"2015","unstructured":"Thom H, Thompson JC, Scott DA, Halfpenny N, Sulham K, Corey GR. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. Curr Med Res Opin. 2015;31(8):1539\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"11892_CR42","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/cid\/cit612","volume":"58","author":"KM Itani","year":"2014","unstructured":"Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2014;58(Suppl 1):S4-9.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"2","key":"11892_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/cid\/ciw750","volume":"64","author":"D Nathwani","year":"2017","unstructured":"Nathwani D, Corey R, Das AF, Sandison T, De Anda C, Prokocimer P. Early clinical response as a predictor of late treatment success in patients with acute bacterial skin and skin structure infections: retrospective analysis of 2 randomized controlled trials. Clin Infect Dis. 2017;64(2):214\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"11892_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130\u20137.","journal-title":"Ann Intern Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11892-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:35:48Z","timestamp":1761903348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11892-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11892"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11892-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1460"}}